Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for
minimally invasive endovascular intervention, and Baptist Health
Lexington, a leading health provider in Kentucky, today announced
that physicians have built upon their two-decades of leadership in
robotic heart care with the successful treatment of first patients
using the newest advancement in the technology, the Genesis Robotic
Magnetic Navigation (RMN) System.
Electrophysiologists at Baptist Health Lexington
were the first globally to pioneer clinical use of Robotic Magnetic
Navigation for the treatment of patients in 2003. The robotic
technology represented an entirely novel way to address heart
rhythm disorders in a minimally invasive procedure with the
benefits of robotic precision and safety. In the ensuing years, the
electrophysiology department, under the leadership of Dr. Gery
Tomassoni, played central roles in advancing the technology and
clinical science: authoring multiple scientific publications,
participating in national clinical studies, guiding technology
developments, and using robotic technology to treat over 1000
cardiac patients, including those with the most complex
conditions.
With the unveiling of the Genesis System,
Baptist Health Lexington has become the first in Kentucky, and one
of the first in the world, to provide the latest advancement in
robotic technology to treat cardiac arrhythmias.
“We are excited to build upon our leading
robotic program and our long legacy of pioneering advanced
technologies to advance care,” says Chris Roty, president of
Baptist Health Lexington. “The adoption of the latest robotic
magnetic navigation system represents our continued commitment to
pursuing the innovative technologies and techniques that benefit
our patients.”
“For twenty years, robotics has been central to
our program offering the highest quality care to a broad range of
heart rhythm patients, including the most complex, challenging, and
underserved,” added Dr. Gery Tomassoni, Director of
Electrophysiology at Baptist Health Lexington. “Many technologies
come and go, but this is an example of a system that has continued
to advance due to the clinical value in enabling safe and reliable
treatment.”
Robotic Magnetic Navigation introduces the
benefits of robotic precision and safety to cardiac ablation, a
common minimally invasive procedure to treat arrhythmias. Tens of
millions of individuals worldwide suffer from arrhythmias –
abnormal heart rhythms that result when the heart beats too
quickly, too slowly, or with an irregular pattern. When left
untreated, arrhythmias may significantly increase the risk of
stroke, heart failure, and sudden cardiac arrest.
Lewis Wilkerson was just one of Dr. Tomassoni’s
many patients who has benefited from the use of Robotic Magnetic
Navigation. In 2006, Lewis realized something was not right with
his heart during one of his regular outdoor runs. His wife
recommended he see their local cardiologist, Dr. Andy Bustin who,
after discovering he had an arrhythmia, referred him to Dr.
Tomassoni. Due to the complexity of Lewis’s arrhythmia, Dr.
Tomassoni recommended a cardiac ablation using the Stereotaxis RMN
system. A pharmacist, as is his wife, Lewis did his research and,
after learning that Dr. Tomassoni has been doing these procedures
since 2003 when the system was first installed at Central Baptist
Hospital, knew that he was in good hands at this critical time in
his life. Three days after his procedure, Lewis was back to his
daily runs.
“The cooperation of my doctors, the expertise of
Dr. Tomassoni, and the equipment he used, all combined to help me
live the life I’m living today”, said Lewis this week. “This new
technology, invested in by Baptist Health Lexington, along with the
expertise of their staff; will continue to help so many Kentuckians
just like me. My wife and I will always be grateful for the
compassion the staff showed us, and the knowledge they have about
the human heart.”
“Our long-term collaboration with Baptist Health
Lexington has been instrumental for technological progress,
scientific discovery, and clinical care,” said David Fischel,
Chairman and CEO of Stereotaxis. “We look forward to expanding the
success of robotic ablation practices for patients suffering from
arrhythmias in Kentucky.”
About
StereotaxisStereotaxis (NYSE: STXS) is the global
leader in innovative robotic technologies designed to enhance the
treatment of arrhythmias and perform endovascular procedures. Its
mission is the discovery, development and delivery of robotic
systems, instruments, and information solutions for the
interventional laboratory. These innovations help physicians
provide unsurpassed patient care with robotic precision and safety,
improved lab efficiency and productivity, and enhanced integration
of procedural information. Stereotaxis’ Robotic Magnetic Navigation
technology is used in the United
States, Europe, Asia, and elsewhere. For more
information, please visit www.Stereotaxis.com or follow us on
Facebook, Twitter, LinkedIn, Instagram, and YouTube.
This press release includes statements that may
constitute "forward-looking" statements, usually containing the
words "believe”, "estimate”, "project”, "expect" or similar
expressions. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially. Factors that would cause or contribute to such
differences include, but are not limited to, the Company's ability
to manage expenses at sustainable levels, acceptance of the
Company's products in the marketplace, the effect of global
economic conditions on the ability and willingness of customers to
purchase its technology, competitive factors, changes resulting
from healthcare policy, dependence upon third-party vendors, timing
of regulatory approvals, the impact of pandemics or other
disasters, and other risks discussed in the Company's periodic and
other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release. There can be no assurance that the
Company will recognize revenue related to its purchase orders and
other commitments because some of these purchase orders and other
commitments are subject to contingencies that are outside of the
Company's control and may be revised, modified, delayed, or
canceled.
Stereotaxis Contacts:David L.
FischelChairman and Chief Executive Officer
Kimberly PeeryChief Financial Officer
314-678-6100investors@stereotaxis.com
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Stereotaxis (AMEX:STXS)
Historical Stock Chart
From Apr 2023 to Apr 2024